α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates
Mechanism of Anti-α-Synuclein Immunotherapy
The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease - Benskey - 2016 - Journal of Neurochemistry - Wiley Online Library
Alpha Synuclein in Parkinson's Disease Diagnostics
Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys - eBioMedicine
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
Alpha-Synuclein aggregation HTRF kit
Initiation and propagation of α-synuclein aggregation in the nervous system, Molecular Neurodegeneration
Frontiers Modeling Parkinson's Disease With the Alpha-Synuclein Protein
α-Synuclein Aggregation in Treatment of Parkinson's Disease
Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies
Interactions between iron and α-synuclein pathology in Parkinson's disease - ScienceDirect
Targeting Alpha Synuclein Aggregation with CBP/p300 Inhibitors: A Novel Approach in Parkinson's Disease Therapeutics
Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
